GlassScriptPhysician profile
Anthony Jerome Porter
NPI 1013957133
$24,466.54
in general payments reported to CMS, 2019-2025
47 companies · $3,736 in 2025
The $3,736 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,062 · 2020: $2,158 · 2021: $3,092 · 2022: $5,631 · 2023: $3,985 · 2024: $3,802 · 2025: $3,736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,079.06 |
| Education | $444.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,993.83 | 2019-2025 | Tremfya, Remicade, Simponi Aria |
| Abbvie INC. | $3,941.02 | 2019-2025 | |
| Ucb, INC. | $2,819.55 | 2019-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $2,026.75 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $1,751.10 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,633.03 | 2019-2025 | |
| Lilly USA, LLC | $1,227.82 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $848.14 | 2019-2025 | Ilumya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $719.40 | 2022-2025 | Spevigo, Cyltezo |
| Leo Pharma INC. | $693.87 | 2019-2025 | Adbry, Spevigo |
| Pfizer INC. | $624.89 | 2022-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $623.72 | 2019-2025 | Siliq, Cabtreo, Jublia |
| Incyte Corporation | $446.26 | 2021-2025 | Opzelura |
| Dermavant Sciences, INC. | $365.39 | 2023-2024 | Vtama |
| Merz North America, INC. | $354.34 | 2021 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $255.99 | 2019-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $215.24 | 2020-2025 | Nemluvio |
| Biofrontera INC. | $211.15 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| E.R. Squibb & Sons, L.L.C. | $191.55 | 2022-2025 | Sotyktu |
| Almirall LLC | $139.30 | 2019-2022 | |
| Strata Skin Sciences, INC. | $114.76 | 2019-2025 | Xtrac |
| Organogenesis INC. | $104.90 | 2023 | Puraply |
| Helsinn Therapeutics (U.S.), INC. | $104.70 | 2019-2023 | Valchlor |
| Paratek Pharmaceuticals, INC. | $95.84 | 2023-2025 | Nuzyra |
| Janssen Scientific Affairs, LLC | $86.28 | 2019 | |
| Journey Medical Corporation | $83.82 | 2020 | |
| Alnylam Pharmaceuticals INC. | $82.10 | 2021-2024 | Givlaari |
| Botanix Sb INC | $78.37 | 2025 | Sofdra |
| Organon LLC | $75.37 | 2025 | Vtama |
| Genentech USA, INC. | $69.58 | 2019-2024 | Erivedge |
| Arcutis Biotherapeutics, INC. | $68.70 | 2023-2025 | Zoryve |
| Mayne Pharma Commercial LLC | $43.01 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $39.13 | 2020 | |
| Sanofi-Aventis U.S. LLC | $35.66 | 2020 | |
| Allergan, INC. | $32.27 | 2020-2022 | |
| Kerecis Limited | $29.86 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Mimedx Group, INC. | $29.74 | 2025 | |
| Tactile Systems Technology INC | $28.55 | 2021 | |
| Kyowa Kirin, INC. | $26.95 | 2024 | Poteligeo |
| Lnhc, INC | $23.75 | 2025 | Zelsuvmi |
| Smith+Nephew, INC. | $22.89 | 2022 | |
| Celgene Corporation | $21.32 | 2024 | Sotyktu |
| Dermira, INC. | $20.20 | 2020 | |
| Encore Dermatology INC. | $19.96 | 2019 | |
| Nabriva Therapeutics, Plc | $15.59 | 2021 | |
| Pierre Fabre Pharmaceuticals, INC. | $15.47 | 2020 | |
| Merck Sharp & Dohme LLC | $15.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.